Clinical trial NCT02433522: Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab
Official title: Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: ANCA-associated Vasculitides
Keywords: ANCA-associated vasculitides
Maintenance treatment
Rituximab
Granulomatosis with polyangiitis
Microscopic polyangiitis
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
Collaborators: name: Roche Pharma AG
First posted: 2015-05-05
Enrollment: 97
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: MAINRITSAN study compared Rituximab and azathioprine as maintenance therapy for ANCA-associated vasculitides. In this study, Rituximab (5 infusions at D1, D15, M6, M12, M18) was superior to azathioprine (2 mg/kg/day) to prevent relapses of AAV 28 months after the inclusion (Guillevin et al. NEJM 2014). Nevertheless, in the follow-up study of MAINRITSAN, up to 30% of patients experienced a relapse 38 months after the last rituximab infusion (unpublished data). Right now, no randomized controlled study has been carried in order to evaluate the best duration of the maintenance treatment with rituximab.

The investigators objective is to evaluate the efficacy of a long term rituximab treatment to prevent relapses of ANCA-associated vasculitis in patients in remission after a first phase of rituximab maintenance treatment.

The investigators will conduct a randomized placebo-controlled trial of a long term rituximab maintenance treatment (46 months) against a conventional maintenance treatment (18 months).


Eligibility criteria: Inclusion Criteria:

First, patients must have been included in MAINRITSAN 2 and in addition to meeting the criteria for inclusion and non-inclusion.

MAINRITSAN 2 inclusion criteria:

* Granulomatosis with Polyangiitis Or microscopic polyangiitis complying Or kidney-limited disease With or without detectable ANCA (anti-neutrophil cytoplasmic antibodies) at the time of diagnosis or relapse, and at remission.
* Who have achieved remission using a treatment combining corticosteroids and an immunosuppressive agent, including corticosteroids, cyclophosphamide IV or oral (the use of another immunosuppressant is allowed, according to the current French guidelines, as well as plasma exchanges and/or IV immunoglobulins, or rituximab).
* Interval of 1 month between the end of the immunosuppressant treatment and the randomization time if cyclophosphamide or methotrexate were used, interval between 4 and 6 months if rituximab was used
* Age \> 18 years without age limit higher when the diagnosis is confirmed.
* Informed and having signed the consent form to take part in the study.

and Patients must meet all of the following criteria:

* In complete remission (BVAS 0) at 28 months of MAINRITSAN2 study.
* Informed patient who accepted to participate in MAINRITSAN 2 and who signed the informed consent to this extension.
* Randomized on the day of the evaluation of the primary endpoint of MAINRITSAN 2 during the visit M28 (last visit of the protocol).

Exclusion Criteria:

* Eosinophilic granulomatosis with polyangiitis (EGPA)
* History of severe allergic manifestations or anaphylactic manifestations following humanized or murine monoclonal antibodies infusions
* Pregnant or breast feeding women. Contraception is required for women who could be pregnant during treatment follow up and during the year following the last infusion.
* Infection by HIV (positive serology), HCV (positive serology), or HBV (HBsAg positive or anti-HBc antibody positive with anti-HBs antibody negative)
* Uncontrolled infection at time of inclusion in the extended follow-up study.
* Other severe bacterial, viral , mycobacterial or fungal infection(s), occurring within the last 3 months before of randomization. A severe infection is defined by the hospitalization, a life or organ threatening.
* Severe chronic obstructive bronchopathy (FEV \< 50% or dyspnea stage III).
* Cardiac failure, stage IV according to the NYHA classification.
* Recent history of coronary artery disease (\<1 month).
* Ongoing malignancy or hematologic disease within 5 years before inclusion.
* Patient with severe immunodepression characterized by clinical manifestations.
* Participation to another concomitant therapeutic study (except observational studies or studies without therapeutic intervention).
* Psychiatric disease that may interfere with the study.
* Non affiliation to a health insurance.
* Uncontrolled severe cardiac disease.

Primary outcomes:
measure: Vasculitis score 2003 (BVAS 2003 )
timeFrame: 28 months
Secondary outcomes:
measure: Number of adverse events,
timeFrame: 28 months
measure: number of patients experiencing at least one adverse event in both arms
timeFrame: 28 months
measure: correlation of ANCA level with the clinical events
timeFrame: 28 months
measure: ANCA level during follow-up
timeFrame: 28 months
measure: correlation B-Lymphocytes CD-19 level with the clinical events
timeFrame: 28 months
measure: B-Lymphocytes CD-19 level during follow-up
timeFrame: 28 months
measure: number of B memory cells during follow-up in both arms
timeFrame: 28 months
measure: correlation number of B memory cells with the clinical events
timeFrame: 28 months
measure: Number of patients with ANCA in each arm
timeFrame: 28 months
measure: Time frame to death in both arms
timeFrame: 28 months
measure: time frame of first minor relapse
timeFrame: 28 months
measure: time frame of first major relapse
timeFrame: 28 months
measure: Cumulated dose of corticosteroid treatment
timeFrame: 28 months
measure: Number and severity of damages
timeFrame: 28 months
measure: number of of gammaglobulins
timeFrame: 28 months
measure: Quality of life : SF36 (The Short Form (36) Health Survey)
timeFrame: 28 months
measure: functional capacities : HAQ (Health Assessment Questionnaire )
timeFrame: 28 months
Other outcomes:
Locations:
city: Paris
country: France
facility: Hopital cochin
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Loic GUILLEVIN, MD-PhD
role: STUDY_CHAIR
References:
citation: Pagnoux C, Guillevin L; French Vasculitis Study Group; MAINRITSAN investigators. Rituximab or azathioprine maintenance in ANCA-associated vasculitis. N Engl J Med. 2015 Jan 22;372(4):386-7. doi: 10.1056/NEJMc1414728. No abstract available.
citation: Charles P, Perrodeau E, Samson M, Bonnotte B, Neel A, Agard C, Huart A, Karras A, Lifermann F, Godmer P, Cohen P, Hanrotel-Saliou C, Martin-Silva N, Pugnet G, Maurier F, Sibilia J, Carron PL, Gobert P, Meaux-Ruault N, Le Gallou T, Vinzio S, Viallard JF, Hachulla E, Vinter C, Puechal X, Terrier B, Ravaud P, Mouthon L, Guillevin L; French Vasculitis Study Group. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial. Ann Intern Med. 2020 Aug 4;173(3):179-187. doi: 10.7326/M19-3827. Epub 2020 Jun 2.